Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Amgen (AMGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 105,034,360
  • Shares Outstanding, K 745,000
  • Annual Sales, $ 21,662 M
  • Annual Income, $ 6,939 M
  • 36-Month Beta 1.14
  • Price/Sales 4.83
  • Price/Book 3.40

Price Performance

See More
Period Period Low Period High Performance
1-Month
138.83 +3.33%
on 12/08/16
152.23 -5.77%
on 11/10/16
-2.97 (-2.03%)
since 11/09/16
3-Month
133.64 +7.34%
on 11/04/16
176.85 -18.89%
on 09/23/16
-23.10 (-13.87%)
since 09/09/16
52-Week
133.64 +7.34%
on 11/04/16
176.85 -18.89%
on 09/23/16
-14.44 (-9.15%)
since 12/09/15

Most Recent Stories

More News
Amgen and Broadcom climb; Restoration Hardware falls

NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:

Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables...

Stock Market News for December 08, 2016

The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

Biosimilar Market 2016-2020 Featuring Key Players - Sandoz, Amgen, Celltrion and Pfizer - Research and Markets

Research and Markets has announced the addition of the "Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)" report to their offering.

Asian stocks advance ahead of ECB decision

SEOUL, South Korea (AP) — Asian shares rose on Thursday after an overnight surge on U.S. markets. Investors were focused the European Central Bank's meeting later in the day.

Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus

This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.

AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society...

How These Biotech Stocks are Faring? -- Celgene, Sarepta Therapeutics, MannKind and Amgen

Today, Stock-Callers.com navigates the Biotech arena to review the most recent performances of Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and...

Amgen/Allergan File for EU Approval of Avastin Biosimilar

Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 146.59
1st Resistance Point 145.02
Last Price 143.45
1st Support Level 141.44
2nd Support Level 139.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.